BindingDB logo
myBDB logout

127 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
28686445 39 Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension.EBI Sun Yat-Sen University
28591512 114 Discovery of a Highly Selective Tankyrase Inhibitor Displaying Growth Inhibition Effects against a Diverse Range of Tumor Derived Cell Lines.EBI A GlaxoSmithKline Company
28406621 65 Discovery of Selective Phosphodiesterase 1 Inhibitors with Memory Enhancing Properties.EBI Dart Neuroscience LLC
28165743 37 Design and Synthesis of Novel and Selective Phosphodiesterase 2 (PDE2a) Inhibitors for the Treatment of Memory Disorders.EBI Dart Neuroscience LLC
8230115 16 Inhibitors of blood platelet cAMP phosphodiesterase. 4. Structural variation of the side-chain terminus of water-soluble 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
1336055 22 Novel cAMP PDE III inhibitors: 1,6-naphthyridin-2(1H)-ones.EBI Sterling Winthrop Pharmaceuticals Research Division
1732525 11 Heteroatom analogues of bemoradan: chemistry and cardiotonic activity of 1,4-benzothiazinylpyridazinones.EBI R. W. Johnson Pharmaceutical Research Institute
1321911 59 Inhibitors of blood platelet cAMP phosphodiesterase. 3. 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives with enhanced aqueous solubility.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
2153210 32 6-Benzoxazinylpyridazin-3-ones: potent, long-acting positive inotrope and peripheral vasodilator agents.EBI R.W. Johnson Pharmaceutical Research Institute
2913296 4 Cardiotonic agents. 1-Methyl-7-(4-pyridyl)-5,6,7,8-tetrahydro-3 (2H)-isoquinolinones and related compounds. Synthesis and activity.EBI Mitsui Toatsu Chemicals Inc.
2536438 10 Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for the treatment of congestive heart failure.EBI Warner-Lambert Company
3385731 12 Cardiotonic agents. Synthesis and inotropic activity of a series of isoquinolin-3-ol derivatives.EBI Ortho Pharmaceutical Corporation
2846839 24 Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazoline.EBI Syntex Research
3039135 16 Synthesis and cardiotonic activity of a series of substituted 4-alkyl-2(1H)-quinazolinones.EBI TBA
3027339 89 Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide (RS-82856).EBI TBA
3027338 20 Inhibitors of cyclic AMP phosphodiesterase. 1. Analogues of cilostamide and anagrelide.EBI TBA
3656349 10 Cardiotonic agents. 6. Synthesis and inotropic activity of 2,4-dihydro-5-[4-(1H-imidazol-1-yl)phenyl]-3H-pyrazol-3-ones: ring-contracted analogues of imazodan (CI-914).EBI Warner-Lambert/Parke-Davis Pharmaceutical Research
3701782 6 Bipyridine cardiotonics: the three-dimensional structures of amrinone and milrinone.EBI TBA
3950907 6 Cardiotonic agents. 3. Synthesis and biological activity of novel 6-(substituted 1H-imidazol-4(5)-yl)-3(2H)-pyridazinones.EBI TBA
3783575 3 Cardiotonic agents. 4. Synthesis and biological evaluation of N-substituted 2,4,4a,5-tetrahydro-3H-indeno[1,2-c]pyridazin-3-ones: rigid structures derived from CI-930 and analogues.EBI TBA
11128646 69 Synthesis and biological evaluation of 2,5-dihydropyrazol.EBI Rhône-Poulenc Rorer
10636238 71 Synthesis and structure-activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indoles: novel PDE4 inhibitors.EBI Institut de Recherche Jouveinal-Parke Davis
9871607 32 Phosphodiesterase inhibitory properties of losartan. Design and synthesis of new lead compounds.EBI Rhône-Poulenc Rorer
27662031 1 Structure-activity relationship (SAR) study and design strategies of nitrogen-containing heterocyclic moieties for their anticancer activities.EBI Hamdard University
27597413 58 Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: Design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings.EBI Southern Medical University
27606546 218 Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.EBI University of Navarra
27490827 24 Discovery and Preclinical Characterization of 6-Chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1H-indole-3-carboxylic Acid (PF-06409577), a Direct Activator of Adenosine Monophosphate-activated Protein Kinase (AMPK), for the Potential Treatment of Diabetic Nephropathy.EBI Pfizer Inc.
27031670 16 Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery.EBI Astex Pharmaceuticals
27301679 21 Design and synthesis of potent and selective pyridazin-4(1H)-one-based PDE10A inhibitors interacting with Tyr683 in the PDE10A selectivity pocket.EBI Takeda Pharmaceutical Company Limited
26881908 13 De Novo Design at the Edge of Chaos.EBI Swiss Federal Institute of Technology (ETH)
26789933 100 Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases.EBI Intra-Cellular Therapies, Inc.
26681511 33 Preparation and optimization of pyrazolo[1,5-a]pyrimidines as new potent PDE4 inhibitors.EBI Sanofi Research Center
26526739 35 Catecholic amides as potential selective phosphodiesterase 4D inhibitors: Design, synthesis, pharmacological evaluation and structure-activity relationships.EBI Southern Medical University
26430878 102 Synthesis of Fluorine-Containing Phosphodiesterase 10A (PDE10A) Inhibitors and the In Vivo Evaluation of F-18 Labeled PDE10A PET Tracers in Rodent and Nonhuman Primate.EBI Washington University School of Medicine
26319621 32 Design and discovery of 2-(4-(1H-tetrazol-5-yl)-1H-pyrazol-1-yl)-4-(4-phenyl)thiazole derivatives as cardiotonic agents via inhibition of PDE3.EBI DaQing Oil Field General Hospital
25592707 31 Synthesis and in vitro characterization of cinnoline and benzimidazole analogues as phosphodiesterase 10A inhibitors.EBI Washington University School of Medicine
26102506 40 Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115.EBI Celgene Corporation
25815146 29 Pyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazines as Selective, Brain Penetrant Phosphodiesterase 2 (PDE2) Inhibitors.EBI Janssen Pharmaceutica N.V.
25866242 55 2-(Isopropylamino)thieno[3,2-d]pyrimidin-4(3H)-one derivatives as selective phosphodiesterase 7 inhibitors with potent in vivo efficacy.EBI Kaken Pharmaceutical Co. Ltd
25801159 36 Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5.EBI CSIR-Indian Institute of Integrative Medicine
25529739 43 Discovery and SAR study of 2-(4-pyridylamino)thieno[3,2-d]pyrimidin-4(3H)-ones as soluble and highly potent PDE7 inhibitors.EBI Kyoto 607-8042
25456383 113 Synthesis and preliminary biological evaluation of potent and selective 2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors with improved solubility.EBI TBA
25432025 34 Discovery of a phosphodiesterase 9A inhibitor as a potential hypoglycemic agent.EBI Sun Yat-Sen University
25221665 33 Structure-Based Design of a Potent, Selective, and Brain Penetrating PDE2 Inhibitor with Demonstrated Target Engagement.EBI Janssen Pharmaceutica NV
24758746 36 Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia.EBI Janssen Research& Development
9873708 16 N-arylrolipram derivatives as potent and selective PDE4 inhibitors.EBI Novartis Horsham Research Center
23200255 50 Phosphodiesterase inhibitors. Part 5: hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration.EBI Kyorin Pharmaceutical Co., Ltd
23260348 91 Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors.EBI Janssen-Cilag S.A.
23149228 60 Discovery of selective biaryl ethers as PDE10A inhibitors: improvement in potency and mitigation of Pgp-mediated efflux.EBI Amgen Inc.
22985069 18 Structure-based discovery of highly selective phosphodiesterase-9A inhibitors and implications for inhibitor design.EBI Sun Yat-Sen University
22834877 119 Current landscape of phosphodiesterase 10A (PDE10A) inhibition.EBI Pfizer Inc.
22780914 35 Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders.EBI Pfizer Inc.
22884989 42 Phosphodiesterase inhibitors. Part 4: design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-4,4-dimethylpyrazolones.EBI Kyorin Pharmaceutical Co., Ltd.
22385507 20 Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds.EBI Instituto de Qu£mica M£dica (CSIC)
22377514 75 The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia.EBI Merck Research Laboratories
20005117 24 Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors.EBI Islamic Azad University
18686943 28 Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease.EBI Matrix Laboratories Limited
18299198 73 CoMFA and HQSAR studies on 6,7-dimethoxy-4-pyrrolidylquinazoline derivatives as phosphodiesterase10A inhibitors.EBI St. John's University
18304812 29 Rhodanine derivatives as novel inhibitors of PDE4.EBI University of Paisley
15887951 29 The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.EBI Monash University (Parkville Campus)
15780616 9 Fused pyrimidine based inhibitors of phosphodiesterase 7 (PDE7): synthesis and initial structure-activity relationships.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
11405657 123 Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives.EBI Tanabe Seiyaku Co., Ltd.
10090791 77 Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.EBI Tanabe Seiyaku Company, Ltd.
8388468 37 Cyclic nucleotide phosphodiesterase inhibition by imidazopyridines: analogues of sulmazole and isomazole as inhibitors of the cGMP specific phosphodiesterase.EBI SmithKline Beecham Pharmaceuticals
2822927 51 Cardiotonic agents. 8. Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity.EBI Warner-Lambert Company
2985781 53 A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.EBI TBA
12824030 67 1,7- and 2,7-naphthyridine derivatives as potent and highly specific PDE5 inhibitors.EBI Tanabe Seiyaku Co., Ltd.
11755362 24 Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: a potent and selective phosphodiesterase type 4D inhibitor.EBI Novartis Pharma AG
22336247 20 Phosphodiesterase inhibitors. Part 3: Design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-dihydropyridazinones with anti-inflammatory and bronchodilatory activity.EBI Kyorin Pharmaceutical Co. Ltd.
22142545 96 Discovery of orally active pyrazoloquinolines as potent PDE10 inhibitors for the management of schizophrenia.EBI Merck Research Laboratories
21988093 316 Highly potent, selective, and orally active phosphodiesterase 10A inhibitors.EBI Pfizer Inc.
21955943 47 Investigation of the pyrazinones as PDE5 inhibitors: evaluation of regioisomeric projections into the solvent region.EBI Pfizer Inc.
21983442 142 Synthesis and structure-activity relationship studies of dihydronaphthyridinediones as a novel structural class of potent and selective PDE7 inhibitors.EBI biocrea GmbH
21705115 37 Synthesis and in vitro evaluation of new analogues as inhibitors for phosphodiesterase 10A.EBI Washington University
21650160 19 Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia.EBI Pfizer Inc.
21530250 73 Phosphodiesterase inhibitors. Part 1: Synthesis and structure-activity relationships of pyrazolopyridine-pyridazinone PDE inhibitors developed from ibudilast.EBI Heriot-Watt University
21330134 4 Discovery of new inhibitor for PDE3 by virtual screening.EBI Korea Research Institute of Chemical Technology
21189023 66 Synthesis and molecular modeling of novel tetrahydro-ß-carboline derivatives with phosphodiesterase 5 inhibitory and anticancer properties.EBI German University in Cairo
21087867 30 Synthesis and SAR study of new phenylimidazole-pyrazolo[1,5-c]quinazolines as potent phosphodiesterase 10A inhibitors.EBI Universit£ di Sassari
20450197 80 Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.EBI Biotie Therapies GmbH
20196613 32 Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5).EBI Pfizer Global Research and Development
19631533 126 Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one.EBI Pfizer Global Research and Development
19628397 3 Design, synthesis and biological evaluation of novel pyridine derivatives as anticancer agents and phosphodiesterase 3 inhibitors.EBI German University in Cairo
19919087 55 Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy.EBI Pfizer Global Research and Development
19836860 5 Discovery of colon tumor cell growth inhibitory agents through a combinatorial approach.EBI German University in Cairo
 71 Imidazotriazinone inhibitors of the Ca2+-calmodulin sensitive phosphodiesterase (PDE I)EBI TBA
 36 Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunctionEBI TBA
19339180 69 The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents.EBI Pfizer Global Research and Development
16275071 26 A new chemical tool for exploring the physiological function of the PDE2 isozyme.EBI Pfizer, Inc.
16263279 37 A new chemical tool for exploring the role of the PDE4D isozyme in leukocyte function.EBI Pfizer, Inc.
16005625 162 Discovery of hydroxamic acid analogs as dual inhibitors of phosphodiesterase-1 and -5.EBI Sumitomo Pharmaceuticals Co., Ltd
15324877 90 Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: Optimization of 5,8-disubstituted derivatives.EBI Pfizer Global Research and Development
15324876 94 Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1.EBI Pfizer Global Research and Development
15324874 169 Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.EBI Pfizer Global Research and Development
15149695 24 New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors.EBI Pfizer Global Research and Development
15125967 30 Identification of purine inhibitors of phosphodiesterase 7 (PDE7).EBI Bristol-Myers Squibb Pharmaceutical Research Institute
15125945 6 PDE2 inhibition by the PI3 kinase inhibitor LY294002 and analogues.EBI Monash University
15080987 20 Synthesis and phosphodiesterase 5 inhibitory activity of new sildenafil analogues containing a phosphonate group in the 5(')-sulfonamide moiety of phenyl ring.EBI Ewha Womans University
15006407 15 Quinolines as extremely potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
12182866 83 8-Aryl xanthines potent inhibitors of phosphodiesterase 5.EBI Novartis Horsham Research Centre
11958981 25 Imidazo[5,1-f]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors.EBI BAYER AG
10197972 133 1-Arylnaphthalene lignan: a novel scaffold for type 5 phosphodiesterase inhibitor.EBI Tanabe Seiyaku Company, Ltd.
9990447 51 Synthesis and evaluation of potent and selective c-GMP phosphodiesterase inhibitors.EBI Schering-Plough Research Institute
9873643 75 Quinazolines: combined type 3 and 4 phosphodiesterase inhibitors.EBI Novartis Pharma AG
6620311 9 Optical resolution, absolute configuration, and activity of the enantiomers of proxyphylline.EBI TBA
6471063 10 Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure.EBI TBA
3585900 10 Cardiotonic agents. 5. 1,2-Dihydro-5-[4-(1H-imidazol-1-yl)phenyl]-6-methyl-2-oxo-3- pyridinecarbonitriles and related compounds. Synthesis and inotropic activity.EBI TBA
2822926 95 Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correlation with in vivo positive inotropic activiEBI Warner-Lambert Company
1654430 51 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones--inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
1321910 237 Inhibitors of blood platelet cAMP phosphodiesterase. 2. Structure-activity relationships associated with 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones substituted with functionalized side chains.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
1311763 14 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase.EBI Syntex Research
22356915 27 Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors.BDB University of North Carolina
15831442 46 Beneficial effects of a new 20-hydroxyeicosatetraenoic acid synthesis inhibitor, TS-011 [N-(3-chloro-4-morpholin-4-yl) phenyl-N'-hydroxyimido formamide], on hemorrhagic and ischemic stroke.BDB Taisho Pharmaceutical Co., Ltd
22284362 91 Identification of biologically active PDE11-selective inhibitors using a yeast-based high-throughput screen.BDB Boston College
17228859 86 Discovery of a series of 6,7-dimethoxy-4-pyrrolidylquinazoline PDE10A inhibitors.BDB Pfizer